149 related articles for article (PubMed ID: 36530577)
1. Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid.
Algorri M; Acharya A; Bernstein J; Cauchon NS; Chen XH; Huynh-Ba K; Krantz C; Li T; Li Y; McLamore S; Roberts SW; Schwinke D; Shah R; Schirmer A; Strickland H; Tang K; Watson T
AAPS Open; 2022; 8(1):19. PubMed ID: 36530577
[TBL] [Abstract][Full Text] [Related]
2. Maximizing Regulatory Review Efficiency: The Evolution of the FDA OCE RTOR Pilot.
Gao YG; Roberts S; Guy A
Ther Innov Regul Sci; 2022 Mar; 56(2):212-219. PubMed ID: 35006588
[TBL] [Abstract][Full Text] [Related]
3. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
[TBL] [Abstract][Full Text] [Related]
4. Meeting Report: N-Nitrosamine Impurity Control Strategies in the Pharmaceutical and Biotechnology Industries.
Roberts SW; Lennard A; Mohan G; Bernstein J; Cauchon NS; Cole S; Curristin N; Huynh-Ba K; Kolz CN; Murti C; Tang K
AAPS J; 2021 Jul; 23(4):94. PubMed ID: 34258657
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R
Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899
[TBL] [Abstract][Full Text] [Related]
6. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP
Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities.
Feng C; Virparia R; Mui ET
Ther Innov Regul Sci; 2021 Jul; 55(4):881-888. PubMed ID: 33913098
[TBL] [Abstract][Full Text] [Related]
8. Project Orbis: Global Collaborative Review Program.
de Claro RA; Spillman D; Hotaki LT; Shum M; Mouawad LS; Santos GML; Robinson K; Hunt M; Healy C; Chan A; Looi YH; Rodrigues C; Rohr UP; Walther C; Pazdur R
Clin Cancer Res; 2020 Dec; 26(24):6412-6416. PubMed ID: 33037016
[TBL] [Abstract][Full Text] [Related]
9. Transitioning Chemistry, Manufacturing, and Controls Content With a Structured Data Management Solution: Streamlining Regulatory Submissions.
Algorri M; Cauchon NS; Abernathy MJ
J Pharm Sci; 2020 Apr; 109(4):1427-1438. PubMed ID: 32004537
[TBL] [Abstract][Full Text] [Related]
10. Conference report: Bioanalysis highlights from the 2012 American Association of Pharmaceutical Scientists National Biotechnology Conference.
Crisino RM; Geist B; Li J
Bioanalysis; 2012 Sep; 4(17):2103-7. PubMed ID: 23013391
[TBL] [Abstract][Full Text] [Related]
11. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
Kajiwara E; Shikano M
Ther Innov Regul Sci; 2020 Jul; 54(4):814-820. PubMed ID: 32557300
[TBL] [Abstract][Full Text] [Related]
12. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Arora S; Narayan P; Ison G; Berman T; Suzman DL; Wedam S; Prowell TM; Ghosh S; Philip R; Osgood CL; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1058-1071. PubMed ID: 34711631
[TBL] [Abstract][Full Text] [Related]
13. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
[TBL] [Abstract][Full Text] [Related]
14. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
[TBL] [Abstract][Full Text] [Related]
15. Advancing Product Quality: a Summary of the Inaugural FDA/PQRI Conference.
Yu LX; Baker J; Berlam SC; Boam A; Brandreth EJ; Buhse L; Cosgrove T; Doleski D; Ensor L; Famulare J; Ganapathy M; Grampp G; Hussong D; Iser R; Johnston G; Kesisoglou F; Khan M; Kozlowski S; Lacana E; Lee SL; Miller S; Miksinski SP; Moore CM; Mullin T; Raju GK; Raw A; Rosencrance S; Rosolowsky M; Stinavage P; Thomas H; Wesdyk R; Windisch J; Vaithiyalingam S
AAPS J; 2015 Jul; 17(4):1011-8. PubMed ID: 25840884
[TBL] [Abstract][Full Text] [Related]
16. Comparability Considerations and Challenges for Expedited Development Programs for Biological Products.
Schrieber SJ; Putnam WS; Chow ECY; Cieslak J; Zhuang Y; Martin SW; Hanson P; Maggio F; Rosado LAR
Drugs R D; 2020 Dec; 20(4):301-306. PubMed ID: 32914381
[TBL] [Abstract][Full Text] [Related]
17. Generic Pharmaceutical Association (GPhA) - 2015 CMC Workshop (June 9-10, 2015 - Bethesda, Maryland, USA).
Komlos D
Drugs Today (Barc); 2015 Jul; 51(7):429-40. PubMed ID: 26261845
[TBL] [Abstract][Full Text] [Related]
18. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
[TBL] [Abstract][Full Text] [Related]
19. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
